Harpoon_logo (002).jpg
Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
October 05, 2021 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences
September 02, 2021 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
August 03, 2021 16:05 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit
April 28, 2021 16:05 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021
April 10, 2021 08:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors
March 24, 2021 17:09 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021
March 11, 2021 13:16 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 10, 2021 16:05 ET | Harpoon Therapeutics
Provided positive update on its four TriTACĀ® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer Nominated first...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in 33rd Annual Roth Conference
March 09, 2021 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update
March 04, 2021 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...